This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
HARVONI and SOVALDI ACCESS in CANADA, UPDATES as of March 26 (for original Press Release scroll to page bottom)
British Columbia UPDATE on SOVALDI/HARVONI TREATMENT CRITERA and ACCESS as of March 26:
- BC PharmaCare Listing Criteria:
http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/ledipasvir-sofosbuvir.html - BC PharmaCare Information for Prescribers – Sofosbuvir-ledipasvir (Harvoni™) for the treatment of chronic hepatitis C infection genotype 1 AND sofosbuvir (Sovaldi®) for chronic hepatitis C infection genotypes 1, 2 and 3:
http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/pdf/ldv-sofosbuvir.pdf - BC PharmaCare Information for Prescribers – Determining fibrosis stage for the treatment of chronic hepatitis:
http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/pdf/fibrosis-info-sheet.pdf - BC PharmaCare Special Authority Request Form 5460 – Ledipasvir–Sofosbuvir for Chronic Hepatitis C (PDF 311K):
http://www2.gov.bc.ca/assets/gov/health/forms/5460fil.pdf
“The rest of Canada” UPDATE on SOVALDI/HARVONI TREATMENT CRITERA and ACCESS as of March 26
These provinces, as is British Columbia, are part of the Pan-Canadian Pharmaceutical Alliance (pCPA – formerly Pan-Canadian Purchasing Alliance) discussions with the pharmaceutical company making these drugs. Negotiations are in progress and a decision is expected shortly: Alberta, Saskatchewan, Nova Scotia, PEI (see more on PEI below), and Newfoundland
Will list according to the NIHB formulary, which should be updated shortly: Nunavut and Northwest Territories
Manitoba
Available as of April 20, 2015. Listing Criteria: Available from EDS office at Manitoba Health. Notice was provided on this formulary bulletin (pg 3): http://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin82.pdf
New Brunswick
Available March 23, 2015. Listing Criteria: http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/formularyupdates/NBDrugPlansBulletin903.pdf
Ontario
Sovaldi covered on Feb. 23, 2015 for genotypes 1,2, and 3.
Harvoni covered on March 24, 2015. Listing Criteria: Not yet posted online. Updated Exceptional Access Program (EAP) information should be posted by March 31, 2015.
PEI (see above also)
NOTE: Holkira Pak (AbbVie interferon-free combo) was covered on Feb. 12, 2015.
Quebec
Sovaldi was broadly covered on June 2, 2014: http://www.catie.ca/en/practical-guides/hepc-in-depth/treatment/treatment-coverage-your-region/quebec
Harvoni: Not formally part of the pCPA discussions. Negotiations are in progress.
New Brunswick
Available March 23, 2015. Listing Criteria: http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/formularyupdates/NBDrugPlansBulletin903.pdf
Yukon
Sovaldi covered on Feb. 23, 2015 for genotypes 1,2, and 3.
Harvoni available March 10, 2015. Listing Criteria: http://www.hss.gov.yk.ca/drugformulary.php (and search “Harvoni”)
ORIGINAL POST:
As of March 24, 2015, Canadians from the province of British Columbia with hepatitis C who are covered by the provincial PharmaCare program will be eligible for reimbursement for new direct-acting antiviral (DAA) drugs HARVONI (sofosbuvir and ledipasvir) and SOVALDI (sofosbuvir). For press release see:
http://www2.news.gov.bc.ca/